ArticleFrontiers in oncology2021
Risk Factors for Central Lymph Node Metastases and Benefit of Prophylactic Central Lymph Node Dissection in Middle Eastern Patients With cN0 Papillary Thyroid Carcinoma.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Prevalence of Occult Central Lymph Node Metastasis by Tumor Size in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.Current oncology (Toronto, Ont.) · 2023Pooled it
- Dual-channel ultrasonic images empowered deep learning: significantly improving prediction of occult central lymph node metastases in solitary papillary thyroid microcarcinoma.Radiology and oncology · 2026Article
- Ultrasound deep learning features for predicting cervical lymph node metastasis in papillary thyroid carcinoma.Frontiers in oncology · 2026Article
- Predictive value of preoperative serum thyroglobulin and anti-thyroglobulin antibodies for central compartment lymph node metastasis in cN0 papillary thyroid carcinoma.Frontiers in molecular biosciences · 2026Article
- Predictive analysis ofOncology letters · 2026Article
- Coexistent Hashimoto's thyroiditis modulates lymph node metastasis burden in papillary thyroid carcinoma: a single-center study in South China.Frontiers in endocrinology · 2026Article
- Deep learning model based on ultrasound images predicts BRAF V600E mutation in papillary thyroid carcinoma.iScience · 2025Article
- [Analysis of risk factors for lymph node metastasis in patients with CN0 papillary thyroid carcinoma].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2024Article
- The application of a clinical-multimodal ultrasound radiomics model for predicting cervical lymph node metastasis of thyroid papillary carcinoma.Frontiers in oncology · 2024Article
- Predicting central lymph node metastasis in patients with papillary thyroid carcinoma based on ultrasound radiomic and morphological features analysis.BMC medical imaging · 2023Article
- Article
- Ultrasound radiomics models based on multimodal imaging feature fusion of papillary thyroid carcinoma for predicting central lymph node metastasis.Frontiers in oncology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProphylactic central lymph node dissection (PCLND) for adult patients with papillary thyroid carcinoma (PTC) is still a matter of debate. Data on incidence, risk and benefits of PCLND in Middle Eastern patients is lacking. Therefore, we aimed to identify the incidence and predictive clinico-pathological and molecular marker of PCLND in adult patients with clinically node negative (cN0) Middle Eastern PTC.
methodsThis retrospective study included 942 adult Middle Eastern patients with cN0 PTC who underwent total thyroidectomy (TT) or TT+PCLND. Clinico-pathological associations of central lymph node metastasis (CLNM) were assessed. Multivariate analysis was performed using logistic regression and Cox proportional hazards model.
results213 patients underwent PCLND and 38.0% (81/213) had positive CLNM. Multivariate analysis demonstrated age ≤55 years (Odds Ratio (OR) = 7.38; 95% Confidence Interval (CI) = 1.59 - 34.31; p = 0.0108), tumor bilaterality (OR = 3.01; 95% CI = 1.01 - 9.21; p = 0.0483), lymphovascular invasion (OR = 2.92; 95% CI = 1.18 - 7.23; p = 0.0206) and
conclusionscN0 Middle Eastern PTC patients treated with PCLND showed a significantly better prognosis. PCLND was effective in improving RFS in Middle Eastern PTC patients and should be encouraged for patients with potential risk factors for CLNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.